| Literature DB >> 33239912 |
Wen-Jie Tang1, Yun-Shi Liang2, Jing Yan3, Yue Hu4, Mei-Li Sun5, Guo-Shun Liu1, Xiao-Huan Pan6, Xin-Hua Wei1, Xin-Qing Jiang1, Yuan Guo1.
Abstract
BACKGROUND: Encapsulated papillary carcinoma (EPC) of the breast is a rare entity. EPC can be underappreciated on percutaneous biopsy, which may require additional procedures if invasion is not recognized preoperatively. We aimed to investigate the magnetic resonance imaging (MRI) phenotypes correlated with preoperative pathological risk stratification for clinical guidance.Entities:
Keywords: breast neoplasms; carcinoma; magnetic resonance imaging; papillary; pathology
Year: 2020 PMID: 33239912 PMCID: PMC7680800 DOI: 10.2147/CMAR.S277980
Source DB: PubMed Journal: Cancer Manag Res ISSN: 1179-1322 Impact factor: 3.989
The Characteristics of 30 Patients with EPCs
| Character | Number | % |
|---|---|---|
| Age-years (median, IQR) | 60 (50–69) | |
| Diameter-mm (median, IQR) | 23.5 (19.3–34.0) | |
| Menopause status | ||
| Pre-menopausal | 8 | 26.7 |
| Post-menopausal | 22 | 73.3 |
| Manifestation | ||
| Nipple discharge | 3 | 10.0 |
| Breast lumps | 23 | 76.7 |
| Pain | 4 | 13.3 |
| Location | ||
| Left | 13 | 43.3 |
| Right | 17 | 56.7 |
| Cancer History | ||
| Breast cancer history | 1 | 3.3 |
| No cancer history | 29 | 96.7 |
| History | ||
| Less than 1 year | 10 | 33.3 |
| More than 1 year | 20 | 66.7 |
| Stable continuously | 8 | 26.7 |
| Rapid growth recently | 12 | 40.0 |
| Masses number | ||
| Single | 26 | 86.7 |
| Multiple | 4 | 13.3 |
| Pathology | ||
| EPC | 19 | 63.3 |
| EPC with invasion | 11 | 36.7 |
| Median time for follow-up (months) | 30.5 | |
| Prognosis | ||
| Alive | 24 | 80.0 |
| Lost follow-up | 6 | 20.0 |
| Dead | 0 | 0.0 |
Association Between EPC Imaging Findings and Pathological Features
| MR Character | EPC (n=19) | EPC with Invasion (n=11) | Statistical value | P value |
|---|---|---|---|---|
| Age-years (median, IQR) | 57 (47–67) | 66 (58–74) | 2.06 | 0.05 |
| Diameter-mm (median, IQR) | 21.0 (19.5–29.0) | 24.0 (19.5–47.0) | 0.93 | 0.36 |
| Number (single/multiple) | 18/1 | 8/3 | −1.68 | 0.33 |
| ADC value (×10−6mm2/s) | 843.4±103.2 | 876.3±128.5 | 0.77 | 0.45 |
| ADC ratio: ADC (necrosis or cystoid degeneration)/ADC (wall) | 2.50±0.23 | 2.41±0.33 | 0.98 | 0.34 |
| T1 hyperintensity | −1.74 | 0.19 | ||
| Present | 3 | 5 | ||
| Absent | 16 | 6 | ||
| T2 signals | −0.75 | 0.61 | ||
| Hypointensity-isointensity | 3 | 3 | ||
| Mixed | 16 | 8 | ||
| DWI signals | −0.38 | 0.80 | ||
| Hyperintensity | 4 | 3 | ||
| Mixed | 15 | 8 | ||
| Enhancement (solid) | −1.12 | 0.58 | ||
| Minor-mild | 1 | 2 | ||
| Moderate and above | 18 | 9 | ||
| TIC pattern | 0.09 | 0.77 | ||
| Progressive | 2 | 1 | ||
| Plateau | 14 | 9 | ||
| Wash-out | 3 | 1 | ||
| Non-mass enhancement surrounding | −0.23 | 0.85 | ||
| Present | 7 | 7 | ||
| Absent | 12 | 4 | ||
| Margin | −2.34 | 0.04 | ||
| Circumscribed | 12 | 2 | ||
| Not Circumscribed | 7 | 9 | ||
| Component | 1.83 | 0.18 | ||
| Mainly solid mass (80–100% solid component) | 9 | 4 | ||
| Mainly cystic mass (80–100% cystic component) | 5 | 0 | ||
| Complex cystic and solid mass (others) | 5 | 7 | ||
| Dilated duct surrounding | −2.20 | 0.09 | ||
| Present | 3 | 6 | ||
| Absent | 16 | 5 | ||
| Axillary Lymph node | −1.31 | 0.70 | ||
| Positive | 0 | 1 | ||
| Negative | 19 | 10 |
Figure 1According to the WHO classification published in 2019, the EPCs were classified into two pathological subtypes: EPC and EPC with invasion. The above is the schematic diagram, MRI and pathological diagram.
Figure 2A 65-year-old woman with EPC with invasion in the right breast. Axial T2WI with fat suppression (A) showed a mass with mixed hyperintensity to hyperintensity. Axial T1WI (B) showed a mass with hypointensity. Axial fat-suppressed contrast-enhanced T1WI (C) and sagittal (D) showed indistinct tumor margin (white arrow). DWI (E) showed a high signal mass, and the signal of the ADC map (F) was complex. (G), Hematoxylin and eosin (H&E) staining (low power) of the breast mass illustrates fibrous capsule was invaded by tumor cells (the pentagram showed fibrous capsule, the black arrow showed tumor cells). (H), H&E staining (low power) showed tumor cell infiltration in the stroma surrounding the tumor, and vascular cancer embolus (red arrow) were seen at high power (I).
Figure 3A 48-year-old woman with pure EPC in left breast. Axial T2WI with fat suppression (A) and T1WI (B) showed two mainly cystic masses, and one of the masses showed high intensity on T1WI images. Axial and sagittal fat-suppressed contrast-enhanced T1WI (C, D) showed the breast mass with circumscribed margin (white arrow). DWI (E) and ADC map (F) showed high signal mass. (G), H&E stain (high power) showed the fibrovascular axis (black arrow), and papillary hyperplasia was seen at low power (H). (I), H&E stain (low power) showed the tumor cells did not invade the fibrous capsule (pentagram).
Treatment in Different EPC Types
| EPC (n=19) | EPC with Invasion (n=11) | |
|---|---|---|
| Types of operation | ||
| Breast-conserving surgery | 14 (46.7%) | 4 (13.3%) |
| Simple mastectomy | 5 (16.7%) | 7 (23.3%) |
| Sentinel lymph node | ||
| Positive | 0 (0.0%) | 1 (3.3%) |
| Negative | 19 (63.3%) | 10 (33.3%) |
| Axillary lymph node | ||
| Positive | 0 (0.0%) | 1 (3.3%) |
| Negative | 19 (63.3%) | 10 (33.3%) |
| Puncture pathology coincidence rate | ||
| Core needle biopsy (CNB) | ||
| Concordant | 5 (22.7%) | 3 (13.6%) |
| Not concordant | 9 (40.9%) | 5 (22.7%) |
| Vacuum-assisted biopsy (VAB) | ||
| Concordant | 3 (37.5%) | 2 (25.0%) |
| Not concordant | 2 (25.0%) | 1 (12.5%) |
The Risk Stratification for EPC of the Breast and Information of Pathology
| EPC (n=19) | EPC with Invasion (n=11) | Statistical value | P value | |
|---|---|---|---|---|
| ER | −1.89 | 0.06 | ||
| Positive | 19 | 9 | ||
| Negative | 0 | 2 | ||
| PR | −1.31 | 0.19 | ||
| Positive | 19 | 10 | ||
| Negative | 0 | 1 | ||
| Her-2 | −1.31 | 0.19 | ||
| Positive | 0 | 1 | ||
| Negative | 19 | 10 | ||
| Ki-67 | −2.11 | 0.04 | ||
| <20% | 9 | 1 | ||
| ≥20% | 10 | 10 | ||
| Molecular subtype | −2.30 | 0.02 | ||
| Luminal A | 9 | 1 | ||
| Luminal B | 10 | 9 | ||
| Her-2 positive | 0 | 1 | ||
| TNBC | 0 | 0 |
Abbreviations: ER, estrogen receptor; PR, progesterone receptor; Her-2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer.